Preclinical evaluation of an engineered oncolytic herpes simplex virus for pediatric osteosarcoma.

10040Background: Osteosarcoma is the most common primary bone tumor in children. For those with relapsed or metastatic disease, the five-year survival rate is approximately 20%, and survivors often...